Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment
- PMID: 6941392
Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment
Abstract
A prospective endoscopic study was carried out in 65 patients with rheumatoid arthritis to assess the prevalence of gastroduodenal lesions on aspirin alone or aspirin plus another anti-inflammatory drug (n = 26). All patients were taking greater than or equal to 8 tablets aspirin/day for greater than or equal to 3 months. Drug therapy consisted of regular, buffered or enteric-coated aspirin +/- one other non-steroidal anti-inflammatory drug or less than or equal to 10 mg prednisone/day. Endoscopic findings were graded as normal, or gastric and/or duodenal erythema, erosions, or ulcer; only the most serious lesion was tabulated. Fifty-three percent of patients on aspirin alone has a gastric ulcer or erosions, and 13% duodenal ulcer or erosions compared to 35% with gastric lesions and 4% with duodenal lesions on aspirin plus a second drug. Twenty-two percent of patients taking regular aspirin had gastric ulcers compared to only 6% taking enteric coated. Patients on enteric coated aspirin and prednisone had only a 10% prevalence of severe gastro-duodenal lesions. In conclusion, the combination of a second anti-inflammatory drug and aspirin therapy did not result in a higher prevalence of gastro-duodenal damage over that produced by aspirin therapy alone. Enteric coated aspirin produced significantly fewer serious lesions than regular or buffered aspirin. The combination of enteric-coated aspirin plus low dose prednisone caused a low prevalence of severe gastro-duodenal lesions.
Similar articles
-
[Aspirin and gastroduodenal toxicity. A double-blind endoscopic study of the effects of placebo, aspirin and lysine acetylsalicylate in healthy subjects].Gastroenterol Clin Biol. 1984 Jan;8(1):28-32. Gastroenterol Clin Biol. 1984. PMID: 6698337 Clinical Trial. French.
-
The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.Aliment Pharmacol Ther. 2006 May 15;23(10):1489-98. doi: 10.1111/j.1365-2036.2006.02912.x. Aliment Pharmacol Ther. 2006. PMID: 16669964 Clinical Trial.
-
Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.J Clin Gastroenterol. 2009 Feb;43(2):130-2. doi: 10.1097/MCG.0b013e3181580e8a. J Clin Gastroenterol. 2009. PMID: 18779739
-
Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.Aliment Pharmacol Ther. 2004 May 15;19(10):1051-61. doi: 10.1111/j.1365-2036.2004.01935.x. Aliment Pharmacol Ther. 2004. PMID: 15142194 Review.
-
Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy.Ital J Gastroenterol Hepatol. 1999;31 Suppl 1:S14-8. Ital J Gastroenterol Hepatol. 1999. PMID: 10379464 Review.
Cited by
-
Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day.Dig Dis Sci. 1985 Jun;30(6):509-12. doi: 10.1007/BF01320255. Dig Dis Sci. 1985. PMID: 3873326
-
Gastrointestinal mucosal lesions. A drug formulation problem.Med Toxicol. 1987 Mar-Apr;2(2):105-11. doi: 10.1007/BF03260009. Med Toxicol. 1987. PMID: 3553832 Review. No abstract available.
-
Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs.Postgrad Med J. 1990 Aug;66(778):639-46. doi: 10.1136/pgmj.66.778.639. Postgrad Med J. 1990. PMID: 2120690 Free PMC article. Clinical Trial.
-
Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin.Dig Dis Sci. 1989 Sep;34(9):1361-4. doi: 10.1007/BF01538069. Dig Dis Sci. 1989. PMID: 2766902 Clinical Trial.
-
NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.Drugs. 1997 Jan;53(1):6-19. doi: 10.2165/00003495-199753010-00002. Drugs. 1997. PMID: 9010646 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical